Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 94% Improvement Relative Risk COVID-19 or flu-like illness 81% Margolin et al. Quercetin for COVID-19 Prophylaxis Does quercetin+combined treatments reduce COVID-19 infections? Retrospective 113 patients in the USA Fewer cases with quercetin+combined treatments (p=0.0032) Margolin et al., J. Evidence-Based Integrative M.., doi:10.1177/2515690X211026193 Favors quercetin Favors control
20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment
Margolin et al., Journal of Evidence-Based Integrative Medicine, doi:10.1177/2515690X211026193
Margolin et al., 20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment, Journal of Evidence-Based Integrative Medicine, doi:10.1177/2515690X211026193
Jul 2021   Source   PDF  
  All Studies   Meta
Retrospective 113 outpatients, 53 (patient choice) treated with zinc, quercetin, vitamin C/D/E, l-lysine, and quina, showing lower cases with treatment. Results are subject to selection bias and limited information on the groups is provided. See [].
risk of case, 94.4% lower, RR 0.06, p = 0.003, treatment 0 of 53 (0.0%), control 9 of 60 (15.0%), NNT 6.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of COVID-19 or flu-like illness, 81.1% lower, RR 0.19, p = 0.01, treatment 2 of 53 (3.8%), control 12 of 60 (20.0%), NNT 6.2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Margolin et al., 6 Jul 2021, retrospective, USA, peer-reviewed, 5 authors, this trial uses multiple treatments in the treatment arm (combined with zinc, vitamin C/D/E, l-lysine, and quina) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperQuercetinAll
Abstract: Original Manuscript 20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment Journal of Evidence-Based Integrative Medicine Volume 26: 1-13 ª The Author(s) 2021 Article reuse guidelines: DOI: 10.1177/2515690X211026193 Leon Margolin, MD, PhD1 , Jeremy Luchins, PhD1 , Daniel Margolin, Bsc1, Michelle Margolin1, and Sanford Lefkowitz, MSc1 Abstract Objectives and Setting. As the lethal COVID-19 pandemic enters its second year, the need for effective modalities of alleviation remains urgent. This includes modalities that can readily be used by the public to reduce disease spread and severity. Such preventive measures and early-stage treatments may temper the immediacy of demand for advanced anti-COVID measures (drugs, antibodies, vaccines) and help relieve strain also on other health system resources. Design and Participants. We present results of a clinical study with a multi-component OTC “core formulation” regimen used in a multiply exposed adult population. Analysis of clinical outcome data from our sample of over 100 subjects  comprised of roughly equal sized regimen-compliant (test) and non-compliant (control) groups meeting equivalent inclusion criteria  demonstrates a strong statistical significance in favor of use of the core formulations. Results. While both groups were moderate in size, the difference between them in outcomes over the 20-week study period was large and stark: Just under 4% of the compliant test group presented flu-like symptoms, but none of the test group was COVID-positive; whereas 20% of the non-compliant control group presented flu-like symptoms, three-quarters of whom (15% overall of the control group) were COVID-positive. Conclusions. Offering a low cost, readily implemented anti-viral approach, the study regimen may serve, at the least, as a stopgap modality and, perhaps, as a useful tool in combatting the pandemic. Keywords COVID-19, SARS-CoV-2, prophylaxis, early-stage treatment, OTC, zinc, ionophores, immunity enhancement, regimen compliance Received March 11, 2021. Received revised May 04, 2021. Accepted for publication May 30, 2021.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop